Acute Infusion Pain Reaction Due to Anti-PD-1 Antibodies for the Treatment of Cutaneous Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa: A Case Report and Review of the Literature
Recessive dystrophic epidermolysis bullosa (RDEB) belongs to a rare group of inherited dermatoses, which are characterised by mucosal and cutaneous fragility. Cutaneous squamous cell carcinoma (CSCC) is a common complication of RDEB. In the severe subtype of RDEB (RDEB-S), CSCC is observed in 90% of...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Case Reports in Dermatological Medicine |
| Online Access: | http://dx.doi.org/10.1155/crdm/4558623 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850185110339452928 |
|---|---|
| author | Vanessa Tran Susan J. Robertson Jamie Young Malcolm Hogg Alesha A. Thai Vanessa Morgan |
| author_facet | Vanessa Tran Susan J. Robertson Jamie Young Malcolm Hogg Alesha A. Thai Vanessa Morgan |
| author_sort | Vanessa Tran |
| collection | DOAJ |
| description | Recessive dystrophic epidermolysis bullosa (RDEB) belongs to a rare group of inherited dermatoses, which are characterised by mucosal and cutaneous fragility. Cutaneous squamous cell carcinoma (CSCC) is a common complication of RDEB. In the severe subtype of RDEB (RDEB-S), CSCC is observed in 90% of the patients by 55 years. CSCC in patients with RDEB follows an aggressive course with the median survival rate of 2.4 years. We report the case of a 51-year-old female with RDEB with recurrent aggressive CSCC of the right lateral-back. She was commenced on cemiplimab, an anti-programmed death receptor-1 (PD-1) antibody, for the management of unresectable locally advanced CSCC; however, she experienced a severe infusion reaction, manifested as back pain, requiring treatment cessation. Despite three incomplete doses, the patient demonstrated a marked response with significant regression of her tumours. Therefore, further treatment was pursued. She was successfully administered cemiplimab under intravenous sedation. This was later complicated by immune-related colitis, necessitating treatment cessation. The patient was transitioned to best supportive care. The patient required inpatient admission for end-of-life care due to her complex analgesia requirements. This case report explores the pathophysiological mechanisms of pain in RDEB and anti-PD-1 antibody therapy and highlights the unique challenges of pain management in RDEB patients. |
| format | Article |
| id | doaj-art-bfd244b40ff14c838eb72cc9e86063df |
| institution | OA Journals |
| issn | 2090-6471 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Dermatological Medicine |
| spelling | doaj-art-bfd244b40ff14c838eb72cc9e86063df2025-08-20T02:16:49ZengWileyCase Reports in Dermatological Medicine2090-64712025-01-01202510.1155/crdm/4558623Acute Infusion Pain Reaction Due to Anti-PD-1 Antibodies for the Treatment of Cutaneous Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa: A Case Report and Review of the LiteratureVanessa Tran0Susan J. Robertson1Jamie Young2Malcolm Hogg3Alesha A. Thai4Vanessa Morgan5Department of DermatologyDepartment of DermatologyDepartment of Anaesthesia and Pain MedicineDepartment of Anaesthesia and Pain ManagementDepartment of OncologyDepartment of DermatologyRecessive dystrophic epidermolysis bullosa (RDEB) belongs to a rare group of inherited dermatoses, which are characterised by mucosal and cutaneous fragility. Cutaneous squamous cell carcinoma (CSCC) is a common complication of RDEB. In the severe subtype of RDEB (RDEB-S), CSCC is observed in 90% of the patients by 55 years. CSCC in patients with RDEB follows an aggressive course with the median survival rate of 2.4 years. We report the case of a 51-year-old female with RDEB with recurrent aggressive CSCC of the right lateral-back. She was commenced on cemiplimab, an anti-programmed death receptor-1 (PD-1) antibody, for the management of unresectable locally advanced CSCC; however, she experienced a severe infusion reaction, manifested as back pain, requiring treatment cessation. Despite three incomplete doses, the patient demonstrated a marked response with significant regression of her tumours. Therefore, further treatment was pursued. She was successfully administered cemiplimab under intravenous sedation. This was later complicated by immune-related colitis, necessitating treatment cessation. The patient was transitioned to best supportive care. The patient required inpatient admission for end-of-life care due to her complex analgesia requirements. This case report explores the pathophysiological mechanisms of pain in RDEB and anti-PD-1 antibody therapy and highlights the unique challenges of pain management in RDEB patients.http://dx.doi.org/10.1155/crdm/4558623 |
| spellingShingle | Vanessa Tran Susan J. Robertson Jamie Young Malcolm Hogg Alesha A. Thai Vanessa Morgan Acute Infusion Pain Reaction Due to Anti-PD-1 Antibodies for the Treatment of Cutaneous Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa: A Case Report and Review of the Literature Case Reports in Dermatological Medicine |
| title | Acute Infusion Pain Reaction Due to Anti-PD-1 Antibodies for the Treatment of Cutaneous Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa: A Case Report and Review of the Literature |
| title_full | Acute Infusion Pain Reaction Due to Anti-PD-1 Antibodies for the Treatment of Cutaneous Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa: A Case Report and Review of the Literature |
| title_fullStr | Acute Infusion Pain Reaction Due to Anti-PD-1 Antibodies for the Treatment of Cutaneous Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa: A Case Report and Review of the Literature |
| title_full_unstemmed | Acute Infusion Pain Reaction Due to Anti-PD-1 Antibodies for the Treatment of Cutaneous Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa: A Case Report and Review of the Literature |
| title_short | Acute Infusion Pain Reaction Due to Anti-PD-1 Antibodies for the Treatment of Cutaneous Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa: A Case Report and Review of the Literature |
| title_sort | acute infusion pain reaction due to anti pd 1 antibodies for the treatment of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa a case report and review of the literature |
| url | http://dx.doi.org/10.1155/crdm/4558623 |
| work_keys_str_mv | AT vanessatran acuteinfusionpainreactionduetoantipd1antibodiesforthetreatmentofcutaneoussquamouscellcarcinomainrecessivedystrophicepidermolysisbullosaacasereportandreviewoftheliterature AT susanjrobertson acuteinfusionpainreactionduetoantipd1antibodiesforthetreatmentofcutaneoussquamouscellcarcinomainrecessivedystrophicepidermolysisbullosaacasereportandreviewoftheliterature AT jamieyoung acuteinfusionpainreactionduetoantipd1antibodiesforthetreatmentofcutaneoussquamouscellcarcinomainrecessivedystrophicepidermolysisbullosaacasereportandreviewoftheliterature AT malcolmhogg acuteinfusionpainreactionduetoantipd1antibodiesforthetreatmentofcutaneoussquamouscellcarcinomainrecessivedystrophicepidermolysisbullosaacasereportandreviewoftheliterature AT aleshaathai acuteinfusionpainreactionduetoantipd1antibodiesforthetreatmentofcutaneoussquamouscellcarcinomainrecessivedystrophicepidermolysisbullosaacasereportandreviewoftheliterature AT vanessamorgan acuteinfusionpainreactionduetoantipd1antibodiesforthetreatmentofcutaneoussquamouscellcarcinomainrecessivedystrophicepidermolysisbullosaacasereportandreviewoftheliterature |